Company
JIYING TECHNOLOGY CO.,LIMITED was established in Hong Kong in May 2019. It is located in the beautiful Hong Kong Science Park, one of the five major international innovation and technology parks in the world. It focuses on the research of advanced technologies in the intersection of life sciences such as clinical medicine, artificial intelligence, pharmacy, and genetics. We continue to develop innovative medical artificial intelligence products and apply them in the medical field to help doctors improve diagnosis and treatment efficiency, protecting patients' lives and health. The company was jointly founded by medical experts, artificial intelligence experts, biology experts and experienced management personnel. 100% of the R&D personnel have a Master degree or above, of which 85% have a Doctorate degree in related fields.
Since its establishment, it has applied for 3 invention patents and 1 utility model patent, and won the 2020 National Finals Award for the National Ministry of Industry and Information Technology's Epidemic Prevention and Control Special Competition; the 2021 ""Heron Creates the Future"" Silicon Valley (U.S.) STIEF Entrepreneurship Award Third Prize, etc. 5 honors, and participated in the 9.8 International Trade Fair organized by the Ministry of Commerce, the 25th MIF in Macau, the 26th Online and other national international exhibitions, one of the Hong Kong World Innovation and Technology Ambassadors in 2022, Hunan Huawei (2022, 2023) Ascend World Computing Silver Award, the 2023 Hong Kong General Chamber of Commerce of Small and Medium Enterprises Special Award, the Medical Innovation Excellence Award jointly organized by the Hong Kong Innovation and Technology Commission, UNESCO, Hong Kong Quality Assurance Agency, and Hong Kong Sustainable Development, the Jury Committee Commendation Award, etc. It has won multiple awards and received many reports from Hong Kong, Mainland China, and world media.
Integrating innovative R&D ideas of artificial intelligence and gene fusion, existing self-developed products include gastrointestinal endoscopy and digestive tract early cancer AI identification system (Genoimage®), CT severe pancreatitis 3D identification auxiliary diagnosis system, portable AI vital signs remote diagnosis and treatment system, Atrial fibrillation AI recognition and early warning system, traditional Chinese medicine health care system, etc. At present, the company has established cooperative relationships with mainland enterprises, medical units, and universities to jointly build a medical ecological chain in specialized fields and provide interdisciplinary life and health protection solutions. Now it has achieved product launch in mainland China, Hong Kong, Southeast Asia, Africa and other countries.
